VRDN FY 2021 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+182.2% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$80M-2690.8% margin

Net Income

-$79M-2680.2% margin

EPS (Diluted)

$-6.66

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$55M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$204M

Total Liabilities

$16M

Stockholders' Equity

$188M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$1M	+182.2%
Gross Profit	$3M	-$27M	+110.9%
Operating Income	-$80M	-$110M	+27.8%
Net Income	-$79M	-$111M	+28.3%